Pharma · Biotech · Life sciences · Healthcare

Most software was never built for regulated science. Axira is.

NexushriLabs builds AI platforms for pharma, biotech, and life sciences, designed by a doctoral scientist for the environments where validation, traceability, and audit are not optional.

Join the waitlist → See Axira
Multi‑omic biomarker discovery Illustrative · 01 / 04
Drag to rotate

A high dimensional feature space reduced to three components. As the scan plane passes, one cluster resolves and is put forward as a candidate, with the path to it recorded.

The operating record

Formed in February. On the federal record by July.

Five months of operation, stated plainly and open to checking. Nexushri LLC is self funded, and everything below is a matter of public record or a filing the company has made.

3
ARPA‑H solution summaries submitted
6+
Platform modules in development
15+
Years in science and research
2026
Formed in Virginia
First five months
February 2026

Nexushri LLC formed.Registered with the Virginia State Corporation Commission.

May 2026

Development commenced on Axira.The first product, a drug intelligence suite.

15 July 2026

Unique Entity Identifier assigned.Registration in the System for Award Management activated on 30 July.

17 July 2026

Three ARPA‑H Solution Summaries submitted.Under the 2026 SBIR solicitation, covering women's health and safety science.

Federal standing

Eligible, registered, and submitting.

Unique Entity Identifier assigned SBIR and STTR eligible SAM.gov registration active Eligible to receive federal awards

Socioeconomic representations, small business certifications, and the full filing history are set out on the federal eligibility page rather than here.

The product · Axira

Most platforms return analytics. Axira returns an answer, and the trail behind it.

A drug intelligence suite for pharmaceutical scientists, clinical researchers, and drug development teams. Five modules are named below, each independently deployable, and a sixth is held back until the provisional filings clear.

M01 Signal detection A safety signal is easy to see once someone has found it and hard to see while it is still forming. Phase 1 · First release M02 Biomarker discovery Multi-omic data produces candidates faster than any team can qualify them. Phase 2 · In development M03 Clinical data intelligence Clinical teams rarely lack data. Phase 3 · Sequenced M04 Sample management A specimen whose chain of custody cannot be reconstructed is a specimen whose results cannot be defended. Phase 3 · Sequenced M05 Target identification Ranked target lists are easy to produce and hard to trust. Phase 3 · Sequenced

Every capability is independently deployable, and they are released one at a time rather than as a single launch. Intellectual property filings for all modules are in progress.

The Axira suite →